Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 9/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HRH2 | P25021 | 1/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.38 |
| ▸ | CASP1 | P29466 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30448090 | 1.00 | TLR7 (0.39) | TLR7LMNAPOLBHRH2ADRA1D | |
| SCHEMBL4620764 | 0.92 | TLR7 (0.34) | TLR7LMNAPOLBHRH2ADRA1D | |
| SCHEMBL14866402 | 0.89 | TLR7 (0.37) | TLR7LMNAPOLBHRH2ADRA1D | |
| SCHEMBL12245236 | 0.87 | TLR7 (0.36) | TLR7LMNAPOLBHRH2ADRA1D | |
| SCHEMBL29988385 | 0.87 | TLR7 (0.39) | TLR7PDE4DPIM1TSHR | |
| SCHEMBL146804 | 0.87 | TLR7 (0.39) | TLR7PDE4DPIM1TSHR | |
| SCHEMBL12245205 | 0.86 | TLR7 (0.38) | TLR7LMNAPOLBHRH2ADRA1D | |
| SCHEMBL12245244 | 0.86 | PIM1 (0.37) | TLR7LMNAPOLBHRH2ADRA1D | |
| SCHEMBL12296518 | 0.85 | TLR7 (0.41) | TLR7LMNAPOLBHRH2ADRA1D | |
| SCHEMBL4979244 | 0.85 | TLR7 (0.45) | TLR7LMNAPOLBHRH2ADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 234 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130096103-A1 | IMIDAZOQUINOLINE COMPOUNDS | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2013-04-18 | — | — | US | claimed |
| US-20110217323-A1 | IMIDAZOQUINOLINE COMPOUNDS | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2011-09-08 | — | — | US | claimed |
| US-20080213308-A1 | Imidazoquinoline Compounds | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2008-09-04 | — | — | US | claimed |
| EP-4585610-A2 | MAKING INFLUENZA VIRUS VACCINES WITHOUT USING EGGS | Seqirus UK Limited (GB) | 2025-07-16 | — | — | EP | disclosed |
| EP-4144368-B1 | RSV IMMUNIZATION REGIMEN | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2025-02-26 | — | — | EP | disclosed |
| EP-3527224-B1 | RSV IMMUNIZATION REGIMEN | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2025-02-26 | — | — | EP | disclosed |
| US-20250042951-A1 | PRE-FUSION RSV F ANTIGENS | NOVARTIS AG (CH) | 2025-02-06 | — | — | US | disclosed |
| US-12139512-B2 | Pre-fusion RSV F antigens | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2024-11-12 | — | — | US | disclosed |
| US-20240299527-A1 | RSV IMMUNIZATION REGIMEN | NOVARTIS AG (CH) | 2024-09-12 | — | — | US | disclosed |
| US-20240299537-A1 | ADJUVANTED VACCINES WITH NON-VIRION ANTIGENS PREPARED FROM INFLUENZA VIRUSES GROWN IN CELL CULTURE | SEQIRUS UK LTD (GB) | 2024-09-12 | — | — | US | disclosed |
| EP-4183412-B1 | RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2024-08-14 | — | — | EP | disclosed |
| WO-2007052056-A1 | ADJUVANTED INFLUENZA VACCINES INCLUDING CYTOKINE-INDUCING AGENTS | NOVARTIS VACCINES AND DIAGNOSTICS SRL (IT) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007052155-A2 | INFLUENZA VACCINE WITH REDUCED AMOUNT OF OIL-IN-WATER EMULSION AS ADJUVANT | NOVARTIS VACCINES AND DIAGNOSTICS SRL (IT) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007052058-A1 | INFLUENZA VACCINES INCLUDING COMBINATIONS OF PARTICULATE ADJUVANTS AND IMMUNOPOTENTIATORS | NOVARTIS VACCINES AND DIAGNOSTICS SRL (IT) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007052055-A1 | ADJUVANTED VACCINES WITH NON-VIRION ANTIGENS PREPARED FROM INFLUENZA VIRUSES GROWN IN CELL CULTURE | NOVARTIS VACCINES AND DIAGNOSTICS SRL (IT) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007052061-A2 | EMULSIONS WITH FREE AQUEOUS-PHASE SURFACTANT AS ADJUVANTS FOR SPLIT INFLUENZA VACCINES | NOVARTIS VACCINES AND DIAGNOSTICS SRL (IT) | 2007-05-10 | — | — | WO | disclosed |
| WO-2006091517-A2 | IMMUNOGENS FROM UROPATHOGENIC ESCHERICHIA COLI | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2006-08-31 | — | — | WO | disclosed |
| WO-2006089264-A2 | PROTEINS AND NUCLEIC ACIDS FROM MENINGITIS/SEPSIS-ASSOCIATED ESCHERICHIA COLI | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2006-08-24 | — | — | WO | disclosed |
| WO-2006064378-A2 | ADJUVANT ACTIVITY OF GASTROINTESTINAL PEPTIDES | DE MAGISTRIS MARIA TERESA (IT) | 2006-06-22 | — | — | WO | disclosed |
| WO-2006031878-A2 | IMIDAZOQUINOLINE COMPOUNDS | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2006-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042951-A1 | PRE-FUSION RSV F ANTIGENS | FURIN, CD69, LY96 | TLR7 485/4885LMNA 480/4885POLB 3894/4885 |
| US-12139512-B2 | Pre-fusion RSV F antigens | FURIN, CD69, LY96 | TLR7 485/4885LMNA 480/4885POLB 3894/4885 |
| US-20130096103-A1 | IMIDAZOQUINOLINE COMPOUNDS | IFNG, IRF3, MYD88 | TLR7 13/4885LMNA 4398/4885POLB 2702/4885 |
| US-20240299527-A1 | RSV IMMUNIZATION REGIMEN | IL5, IL15, IFNG | TLR7 48/4885LMNA 4368/4885POLB 1481/4885 |
| US-20110217323-A1 | IMIDAZOQUINOLINE COMPOUNDS | IFNG, IRF3, MYD88 | TLR7 13/4885LMNA 4398/4885POLB 2702/4885 |
| US-20240299537-A1 | ADJUVANTED VACCINES WITH NON-VIRION ANTIGENS PREPARED FROM INFLUENZA VIRUSES GROWN IN CELL CULTURE | LY96, PHOSPHO1, ASGR1 | TLR7 73/4885LMNA 2986/4885POLB 1062/4885 |
| US-20080213308-A1 | Imidazoquinoline Compounds | IFNG, IRF3, MYD88 | TLR7 13/4885LMNA 4398/4885POLB 2702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.